<sup>18</sup>F-氟代脱氧葡萄糖PET及PET-CT在淋巴瘤中的临床应用

华逢春; 管一晖; 赵军

¹⁸F-氟代脱氧葡萄糖PET及PET-CT在淋巴瘤中的临床应用

华逢春 , 管一晖 , 赵军

文章导航 > 国际放射医学核医学杂志 > 2005, 29 > 5: (216-219,226)

引用本文:

Citation:

¹⁸F-氟代脱氧葡萄糖PET及PET-CT在淋巴瘤中的临床应用

200235 上海, 复旦大学附属华山医院PET中心
中图分类号: R814.42;R817.4

¹⁸F-FDG PET and PET-CT imaging in lymphoma

PET Center, Huashan Hospital Fudan University, Shanghai 200235, China
CLC number: R814.42;R817.4

摘要: PET在淋巴瘤的分期、再分期、疗效评价及预后判断中具有重要价值,PET-CT则集中了PET的功能显像与CT的解剖显像的双重优势,对淋巴瘤病灶的定位、定性诊断的准确性更高。
- 正电子发射体层显像 /
- 计算机体层成像 /
- ¹⁸F-氟代脱氧葡萄糖 /
- 淋巴瘤
Abstract: PET imaging plays an important role in staging, restaging, evaluating the treatment effects and the prognosis of the lymphoma. PET-CT realized the fuse of functional and anatomic imaging in one gantry and showed more values in clinical diagnosis. It makes the location and characterization of the lesions more accurate.
- positron emission tomography /
- computed tomography /
- ¹⁸F-fluorodeoxyglucose /
- lymphoma
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Hoh CK, Glaspy J, Rosen P, et al. Whole-body ¹⁸F-FDG PET imagin g for staging of Hodgkin's disease and lymphoma[J]. J Nucl Med, 1997, 38(3):343-348.
[2]	Schöder H, Meta J, Yap C, et al. Effect of whole-body ¹⁸F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma[J]. J Nucl Med, 2001, 42(8):1139-1143.
[3]	Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease:coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?[J]. Radiology, 2004, 232(3):823-829.
[4]	Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography[J]. Blood, 1998, 91(9):3340-3346.
[5]	Moog F, Bangerter M, Kotzerks J, et al. ¹⁸F-fluorodeoxyglucose positron emission tomography as a new approach to detect lymphomatous bone marrow[J]. J Clin Oncol, 1998, 16(2):603-609.
[6]	Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma:assessment of chemotherapy with fluorodeoxyglucose[J]. Blood, 1998, 91(12):4464-4471.
[7]	Mikhaeel NG, Timothy AR, O'Doherty MJ, et al. ¹⁸F-FDG PET as a prognostic indicator in the treatment of aggressive non-Hodgkins lym phoma:comparison with CT[J]. Leuk Lymphoma,2000, 39(5-6):543-553.
[8]	Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor ¹⁸F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma[J]. Haematologica, 2000, 85(6):613-618.
[9]	Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography with Fluorine-18 Fluorodeoxyglucose([¹⁸F]-FDG) after first-line chemotherapy in non-Hodgkin's lymphoma:[¹⁸F]FDG-PET a valid alternative to conventional diagnostic methods?[J]. J Clin Oncol, 2001, 19(2):414-419.
[10]	Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using ¹⁸F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease[J]. Blood, 2001, 98(10):2930-2934.
[11]	Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after one cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease[J]. J Nucl Med, 2002, 43(8):1018-1027.
[12]	Freudenberg LS, Antoch G, Schutt P, et al. FDG PET-CT in restaging of patients with lymphoma[J]. Eur J Nucl Med Mol Imaging, 2004, 31(3):325-329.
[13]	Allen-Auerbach M, Quon A, Weber WA, et al. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma[J]. Mol Imaging Biol, 2004, 6(6):411-416.
[14]	Hoffmann M. ¹⁸F-fluorodeoxyglucose positron emission tomography(¹⁸F-FDG PET) for assessment of enteropathy-type T cell lymphoma[J]. Gut, 2003, 52(1):347-351.
[15]	Castellucci P, Zinzani P, Pourdehnad M, et al. (¹⁸)F-FDG PET in malignant lymphoma:significance ofpositive findings[J]. Eur J Nucl Med MolImaging, 2005,32(7):749-756.

[1]	吴湖炳 . ¹⁸F-氟代脱氧葡萄糖PET-CT在头颈部肿瘤中的应用价值. 国际放射医学核医学杂志, 2005, 29(5): 205-209.
[2]	刘建军 , 黄钢 . ¹⁸F-氟代脱氧葡萄糖PET和PET-CT在转移性骨肿瘤中的应用研究. 国际放射医学核医学杂志, 2005, 29(5): 213-216.
[3]	赵晋华 . ¹⁸F-FDG PET在淋巴瘤分期和治疗反应评价中的价值. 国际放射医学核医学杂志, 2004, 28(5): 210-212.
[4]	张立颖 . ¹⁸F-FDG PET显像在恶性淋巴瘤中的应用. 国际放射医学核医学杂志, 2001, 25(1): 10-12.
[5]	季仲友 . PET-CT中诊断性CT的必要性与临床应用. 国际放射医学核医学杂志, 2005, 29(5): 197-200.
[6]	董孟杰 , 林祥通 , 赵军 . PET-CT在卵巢癌中的临床应用价值. 国际放射医学核医学杂志, 2005, 29(5): 209-213.
[7]	陈香 , 赵军 , 管一晖 . PET-CT常见伪影. 国际放射医学核医学杂志, 2005, 29(5): 201-205.
[8]	蔡莉 , 李彦生 . 氟代脱氧葡萄糖与氨基酸PET在脑肿瘤中的对比研究. 国际放射医学核医学杂志, 2005, 29(1): 10-14.
[9]	袁志斌 . 正电子肿瘤阳性显像剂¹⁸F-AMT. 国际放射医学核医学杂志, 2002, 26(5): 193-195.
[10]	廖思锶 , 赵晋华 . 非¹⁸F-FDG PET分子显像在淋巴瘤中的应用进展. 国际放射医学核医学杂志, 2024, 48(): 1-6. doi: 10.3760/cma.j.cn121381-202308029-00399
[11]	段钰 , 邓小虎 , 徐迟峰 , 周海中 . 面部原发性外周T细胞淋巴瘤-非特指型¹⁸F-FDG PET/CT显像一例. 国际放射医学核医学杂志, 2017, 41(6): 455-457. doi: 10.3760/cma.j.issn.1673-4114.2017.06.014